The IIF.dx test provides an analysis of an individual’s DNA, predicts the patient’s immune response in a range of major disease states and facilitates the optimal treatment at a high level of conﬁdence.
Recent clinical data analysed using the GMDx platform has shown a consistent 80% success rate in predicting responders vs non-responders to immunotherapy.
In the future, this breakthrough capability may provide the confidence to advance immunotherapy to a more targeted first-line or second-line treatment.
This will accelerate patient response and recovery and improve likelihood of achieving a Clinically Sustainable Benefit
Progressive product development and commercialisation will focus on major disease states to support clinicians to make better informed therapeutic decisions for their patients.